X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (696) 696
Publication (51) 51
Book Review (17) 17
Book Chapter (8) 8
Magazine Article (3) 3
Conference Proceeding (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (526) 526
index medicus (399) 399
angioedema (260) 260
female (260) 260
hereditary angioedema (250) 250
male (227) 227
immunology (213) 213
allergy (181) 181
adult (172) 172
angioneurotic edema (170) 170
middle aged (159) 159
management (124) 124
bradykinin (123) 123
aged (111) 111
edema (108) 108
angioedema - chemically induced (103) 103
adolescent (96) 96
diagnosis (94) 94
angioedemas, hereditary - drug therapy (93) 93
mortality (89) 89
c1 inhibitor (85) 85
patients (84) 84
angiotensin-converting enzyme inhibitors - adverse effects (78) 78
risk factors (77) 77
care and treatment (75) 75
c1 inhibitor deficiency (74) 74
medicine, general & internal (74) 74
angioedema - diagnosis (70) 70
child (68) 68
urticaria (68) 68
allergy and immunology (66) 66
drug therapy (64) 64
therapy (63) 63
complement c1 inhibitor protein - therapeutic use (62) 62
angioneurotic-edema (60) 60
angioedemas, hereditary - diagnosis (58) 58
young adult (58) 58
treatment outcome (56) 56
abridged index medicus (53) 53
internal medicine (52) 52
research (52) 52
deficiency (51) 51
prophylaxis (51) 51
mutation (50) 50
attacks (49) 49
plasma (49) 49
anaphylaxis (48) 48
angioedema - drug therapy (48) 48
diagnosis, differential (48) 48
enzymes (48) 48
pharmacology & pharmacy (48) 48
angioedema - genetics (47) 47
acute attacks (46) 46
angioedema - therapy (46) 46
icatibant (46) 46
medicine & public health (46) 46
retrospective studies (46) 46
analysis (44) 44
health aspects (44) 44
ace inhibitors (43) 43
allergies (43) 43
c1-inhibitor (43) 43
angiotensin (42) 42
concentrate (42) 42
quality of life (42) 42
dermatology (41) 41
angioedema - etiology (40) 40
animals (40) 40
c1 esterase inhibitor (39) 39
child, preschool (39) 39
bradykinin - analogs & derivatives (38) 38
c1 inhibitor concentrate (38) 38
c1-inhibitor deficiency (37) 37
complement c1 inhibitor protein (37) 37
pediatrics (37) 37
children (36) 36
epidemiology (36) 36
medicine (36) 36
pregnancy (36) 36
aged, 80 and over (35) 35
kallikrein (35) 35
quality-of-life (35) 35
angiotensin-converting enzyme inhibitors - therapeutic use (34) 34
asthma (34) 34
disease (34) 34
hypertension (34) 34
angioedemas, hereditary - therapy (33) 33
bradykinin - therapeutic use (32) 32
time factors (32) 32
treatment (32) 32
angioedema - epidemiology (31) 31
hypersensitivity (31) 31
review (31) 31
abdomen (30) 30
complement c1 inactivator proteins - therapeutic use (30) 30
heart failure (30) 30
symptoms (30) 30
acquired angioedema (29) 29
angioedemas, hereditary - genetics (29) 29
ecallantide (29) 29
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (679) 679
French (10) 10
German (6) 6
Spanish (4) 4
Japanese (3) 3
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 09/2003, Volume 362, Issue 9386, pp. 772 - 776
Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients with chronic heart failure (CHF). A substantial proportion of patients, however,... 
CONTEMPORARY MANAGEMENT | MORTALITY | MEDICINE, GENERAL & INTERNAL | MORBIDITY | RECEPTOR BLOCKERS | IMPROVEMENT | DYSFUNCTION | PROGRAM | ENALAPRIL | RANDOMIZED TRIAL | ANGIOEDEMA | Ventricular Dysfunction, Left - epidemiology | Cough - chemically induced | Follow-Up Studies | Angiotensin Receptor Antagonists | Cardiac Output, Low - epidemiology | Comorbidity | Humans | Male | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hypotension - chemically induced | Heart Failure - drug therapy | Ventricular Dysfunction, Left - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Kidney Diseases - chemically induced | Female | Tetrazoles - therapeutic use | Aged | Cardiac Output, Low - drug therapy | Heart Failure - epidemiology | Benzimidazoles - therapeutic use | Heart failure | Evaluation | Drug therapy | Candesartan | Angiotensin II receptor blockers | Disease management | Clinical outcomes | Morbidity | Heart | Renal function | Heart attacks | Laboratories | Angioplasty | Beta blockers | Anaphylaxis | Dyspnea | Enzyme inhibitors | Motivation | Peptidyl-dipeptidase A | Patient safety | Heart diseases | Drug dosages | Edema | Enzymes | Stroke | Mortality | Angina pectoris | Patients | Hypotension | Cough | Intolerance | Inhibitors | Converting | Angiotensin | Diabetes | Ventricle | Cardiovascular diseases | ACE inhibitors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 993 - 1004
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2019, Volume 381, Issue 17, pp. 1609 - 1620
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
This large trial compared the angiotensin-receptor blocker telmisartan, the angiotensin-converting–enzyme inhibitor ramipril, and combination therapy with both... 
CHRONIC HEART-FAILURE | MEDICINE, GENERAL & INTERNAL | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | DISEASE | DOUBLE-BLIND | CANDESARTAN | SYSTOLIC DYSFUNCTION | COMBINATION | CONVERTING-ENZYME-INHIBITORS | RANDOMIZED TRIAL | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2007, Volume 119, Issue 4, pp. 1018 - 1019
Journal Article
Journal Article